Evidence map›Paper›PMID 35312066›Full record

ArticleJournal of cellular physiology2022

Yes-associated protein activation potentiates glycogen synthase kinase-3 inhibitor-induced proliferation of neonatal cardiomyocytes and iPS cell-derived cardiomyocytes.

Yusuke Kametani, Shota Tanaka, Yuriko Wada, Shota Suzuki, Ayaka Umeda, Kosuke Nishinaka, Yoshiaki Okada, Makiko Maeda, Shigeru Miyagawa, Yoshiki Sawa and 2 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of cellular physiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.2field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Yusuke KametaniLaboratory of Clinical Science and Biomedicine, Graduate School of Pharmaceutical Sciences, Osaka University, Suita City, Osaka, Japan.
Shota TanakaLaboratory of Clinical Science and Biomedicine, Graduate School of Pharmaceutical Sciences, Osaka University, Suita City, Osaka, Japan.
Yuriko WadaLaboratory of Clinical Science and Biomedicine, Graduate School of Pharmaceutical Sciences, Osaka University, Suita City, Osaka, Japan.
Shota SuzukiLaboratory of Clinical Science and Biomedicine, Graduate School of Pharmaceutical Sciences, Osaka University, Suita City, Osaka, Japan.
Ayaka UmedaLaboratory of Clinical Science and Biomedicine, Graduate School of Pharmaceutical Sciences, Osaka University, Suita City, Osaka, Japan.
Kosuke NishinakaLaboratory of Clinical Science and Biomedicine, Graduate School of Pharmaceutical Sciences, Osaka University, Suita City, Osaka, Japan.
Yoshiaki OkadaLaboratory of Clinical Science and Biomedicine, Graduate School of Pharmaceutical Sciences, Osaka University, Suita City, Osaka, Japan.
Makiko MaedaLaboratory of Clinical Pharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, Suita City, Osaka, Japan.
Shigeru MiyagawaDepartment of Cardiovascular Surgery, Graduate School of Medicine, Osaka University, Suita City, Osaka, Japan.
Yoshiki SawaDepartment of Cardiovascular Surgery, Graduate School of Medicine, Osaka University, Suita City, Osaka, Japan.
Masanori ObanaLaboratory of Clinical Science and Biomedicine, Graduate School of Pharmaceutical Sciences, Osaka University, Suita City, Osaka, Japan.ORCID 0000-0002-3209-2208
Yasushi FujioLaboratory of Clinical Science and Biomedicine, Graduate School of Pharmaceutical Sciences, Osaka University, Suita City, Osaka, Japan.
Osaka City University · JPOsaka Gakuin University · JP

Funding

Hyogo Science and Technology AssociationJapan Agency for Medical Research and Development JP21am0101084Japan Agency for Medical Research and Development JP21am0101123Ministry of Education, Culture, Sports, Science and Technology 18H02603Ministry of Education, Culture, Sports, Science and Technology 18K19545
6 · The paper itself

Abstract

Because mammalian cardiomyocytes largely cease to proliferate immediately after birth, the regenerative activity of the heart is limited. To date, much effort has been made to clarify the regulatory mechanism of cardiomyocyte proliferation because the amplification of cardiomyocytes could be a promising strategy for heart regenerative therapy. Recently, it was reported that the inhibition of glycogen synthase kinase (GSK)-3 promotes the proliferation of neonatal rat cardiomyocytes (NRCMs) and human iPS cell-derived cardiomyocytes (hiPSC-CMs). Additionally, Yes-associated protein (YAP) induces cardiomyocyte proliferation. The purpose of this study was to address the importance of YAP activity in cardiomyocyte proliferation induced by GSK-3 inhibitors (GSK-3Is) to develop a novel strategy for cardiomyocyte amplification. Immunofluorescent microscopic analysis using an anti-Ki-67 antibody demonstrated that the treatment of NRCMs with GSK-3Is, such as BIO and CHIR99021, increased the ratio of proliferative cardiomyocytes. YAP was localized in the nuclei of more than 95% of cardiomyocytes, either in the presence or absence of GSK-3Is, indicating that YAP was endogenously activated. GSK-3Is increased the expression of β-catenin and promoted its translocation into the nucleus without influencing YAP activity. The knockdown of YAP using siRNA or pharmacological inhibition of YAP using verteporfin or CIL56 dramatically reduced GSK-3I-induced cardiomyocyte proliferation without suppressing β-catenin activation. Interestingly, the inhibition of GSK-3 also induced the proliferation of hiPSC-CMs under sparse culture conditions, where YAP was constitutively activated. In contrast, under dense culture conditions, in which YAP activity was suppressed, the proliferative effects of GSK-3Is on hiPSC-CMs were not detected. Importantly, the activation of YAP by the knockdown of α-catenin restored the proproliferative activity of GSK-3Is. Collectively, YAP activation potentiates the GSK-3I-induced proliferation of cardiomyocytes. The blockade of GSK-3 in combination with YAP activation resulted in remarkable amplification of cardiomyocytes.

Indexed as

Induced Pluripotent Stem CellsMyocytes, CardiacAnimalsbeta CateninCell ProliferationGlycogen Synthase Kinase 3Glycogen Synthase Kinase 3 betaMammalsRatsYAP-Signaling Proteinsbeta CateninGlycogen Synthase Kinase 3Glycogen Synthase Kinase 3 betaYAP-Signaling Proteinscardiomyocytecateninscell proliferationregenerationsignal transduction

Identifiers

PMID35312066
PMCPMC9311433
OpenAlexW4221094025

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.